ResultsIQ

ResultsIQ › Latest results › Nephrocare Health Services Limited

Nephrocare Health Services Limited Q2 FY27 earnings call summary

NSE: NEPHROPLUS · BSE: 544647

Earnings call of 4 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹303 cr, up 23.5%, with medium-term guidance of 15% to 20% revenue growth reiterated as margins compress about 80 basis points.

Key takeaways

  1. Q2 revenue ₹303 cr, up 23.5% year on year; H1 revenue ₹585 cr, up 23.6%.
  2. Guidance Medium-term revenue growth of 15% to 20% over three to four years reiterated; no annual guidance given.
  3. Margin change H1 FY27 EBITDA margin 23.0% against FY26 23.8%, about 80 basis points lower on new-country investment.
  4. Growth driver International mix reached about 47% of revenue, up from 42% in FY26, lifting revenue per treatment.
  5. Main risk Saudi tender has a binary outcome and management cannot assure winning a region.

Original filing on BSE

Nephrocare Health Services Limited Q2 FY27 results

As filed: Revenue ₹303 cr, EBITDA ₹67.1 cr, PAT ₹33.5 cr, EBITDA margin 22.1%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹303 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.9% in 30 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Nephrocare Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.